As of June 30, 2017, BioSpecifics has received over $120 million from partnerships under the XIAFLEX franchise.

BioSpecifics is partnered with Endo for injectable collagenase (marketed in the U.S. under the trade name XIAFLEX) and Endo continues to manage the research and development of XIAFLEX for their licensed indications.

Under the terms of the partnership agreement, BioSpecifics is eligible for future low double-digit royalties as a percentage of worldwide net sales (independent of clinical indication, territory and sales volume), additional mark-up on cost of goods sold (COGS) in U.S. and sales made in any other country where Endo sells the product directly or through affiliate sublicensees and modest milestones for additional indications and regulatory submissions worldwide. Currently licensed rights cover the indications of Dupuytren's contracture, Peyronie's disease, frozen shoulder, cellulite, lateral hip fat, plantar fibromatosis and canine lipoma.

Ex-U.S. collaborations include the following, of which, BioSpecifics in entitled to a specified percentage of potential regulatory milestones and royalties that Endo receives from its sublicensees:


  • Swedish Orphan Biovitrum AB (Sobi) for the long-term development, supply and commercialization of Xiapex (collagenease clostridium histolyticum). Under the agreement, Sobi has exclusive rights to commercialize Xiapex for Dupuytren's contracture and Peyronie's disease in 28 EU member countries, Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth of Independent countries, including Russia and Turkey, and 22 Middle Eastern and North African countries.
  • Asahi Kasei for the marketing of XIAFLEX for the treatment of Dupuytren's contracture and the development and commercialization of XIAFLEX for Peyronie's disease in Japan.